Natera Inc
NTRA
Market Cap$22.13B
Close$
Earnings Call Q3 2024
November 12, 2024 - AI Summary
Record Revenue Growth: Natera reported $439.8 million in revenue for Q3 2024, a 64% increase year-over-year. This significant growth is attributed to a 24% increase in test volumes, particularly in oncology tests which rose by 54%.
Strong Cash Generation: The company generated $34.5 million in cash flow during the quarter, marking its first meaningful cash generation after a couple of break-even quarters. Full-year cash generation has been updated to a forecast of $50 million to $75 million, indicating a positive shift from an initial expectation of a $50 million loss.
ASP Improvements: The average selling price (ASP) for Signatera climbed to approximately $1,050, reflecting a steady upward trajectory. This shift is expected to continue as Natera anticipates improved reimbursement from Medicare Advantage plans and potential contributions from state biomarker laws.
Exclusive for Stockcircle Pro members
Sign up
$-165.48
198.7% downside
Current Fair Value
198.7% downsideOvervalued by 198.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.13 Billion |
|---|---|
| Enterprise Value | $21.72 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.78 |
| Beta | 1.53 |
| Outstanding Shares | 123,775,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -96.63 |
|---|---|
| PEG | 136.06 |
| Price to Sales | 13.97 |
| Price to Book Ratio | 23.94 |
| Enterprise Value to Revenue | 14.18 |
| Enterprise Value to EBIT | -89.71 |
| Enterprise Value to Net Income | -102 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Natera Inc
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operat...